Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
AZD5462 (Pexerelgon, AZD-5462) | RXFP1 agonist | Probechem Biochemicals
AZD5462 | RXFP receptor | TargetMol
AstraZeneca JMC Reports on RXFP1 Agonist AZD5462
AZD5462 | CAS 2787501-83-9 | AbMole BioScience | AZD5462 Price
化合物 AZD5462 | 2787501-83-9
Chemspace | Analogs to New Biological Tool Compounds | AZD5462
A Phase 1b Randomized Clinical Trial of AZD5462 and Dapagliflozin in ...
WO2025036918A1 - Compound azd5462 for use in the treatment of heart ...
Estudio sobre el efecto de AZD5462 en pacientes con insuficiencia ...
Multi-kg Manufacture of AZD5462 Part 1: The Fragments, Featuring C−H ...
AZD5462 | Ryuichi Fuchigami
Badanie AZD5462 u pacjentów ze stabilną przewlekłą niewydolnością serca
Small Molecule Highlights #24 – April 2024 – Dalriada Drug Discovery
AstraZeneca leads the development of small molecule RXFP1 agonists
ChemAIRS to Investigate Synthesis Plan for AZD5462: A RXFP1 Agonist for ...
AZD-5462 | Selleck Chemicals
Discovery of Clinical Candidate AZD5462, a Selective Oral Allosteric ...
阿斯利康口服RXFP1激动剂AZD5462片首次在中国获批临床，拟治疗心力衰竭
RXFP1受体成心血管新药研发焦点，阿斯利康AZD5462片获批临床_摩熵医药
AZD-5462(AZD-5462) - 药物靶点：RXFP1_在研适应症：慢性心力衰竭，心脏衰竭_专利_临床_研发
阿斯利康「抗心衰1类化药」在华申报临床 研究开发 | 华源医药网
AZD-5462(AZD-5462) - 药物靶点：RXFP1_在研适应症：慢性心力衰竭，慢性肾病，心脏衰竭_专利_临床_研发
Advancing Isotope Labeling Technologies at AstraZeneca through Academic ...
RXFP1受体成心血管新药研发焦点，阿斯利康AZD5462片获批临床_摩熵医药(原药融云)
心力衰竭治疗新曙光？阿斯利康口服松弛素药物AZD5462引发医学界广泛关注_患者_新药_临床
Escape Flatland | 近期两个临床分子示例 - 知乎
Safety, tolerability, and pharmacokinetics of AZD5462, a small molecule ...
'Directivo de la semana': Pascal Soriot y AstraZeneca dem...
AZD5462，Biorbyt，orb1686198价格_品牌:Biorbyt-丁香通
Discovery of Clinical Candidate AZD0095, a Selective Inhibitor of ...
Mechanistic Understanding of Solid–Solid Phase Transition Based on In ...
阿斯利康1类新药首次在中国获批临床，拟治疗心力衰竭_研究_官网_心脏
How does AstraZeneca's PARP inhibitor differentiate?
Therapeutic Antibody Discovery: From Target to Candidate
Discovery of the Clinical Candidate MAK683: An EED-Directed, Allosteric ...
Ligand-activated RXFP1 gene therapy ameliorates pressure overload ...
A Study Designed to Assess the Mass Balance Recovery, Absorption ...
Identification of a distal RXFP1 gene enhancer with differential ...
AZD5438 | ≥99%(HPLC) | Selleck | CDK 阻害剤
